A total of 152 PB samples, prospectively collected from the 33 patients enrolled in the study, were analyzed by applying our multi-antigenic myeloma-specific (here referred to as “MaMs”) T-cell assay, based on IFN-γ ELISpot technology. The gene discussed is IFNG; the disease is plasma cell myeloma.